Northwestern Mutual Wealth Management
NAVB

Northwestern Mutual Wealth Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-110
Closed -$10 – 3618
2023
Q2 		$10 Buy
+110
New +$18 ﹤0.01% 3313
2022
Q1 		– Sell
-237
Closed – – 3565
2021
Q4 		$0 Buy
+237
New +$334 ﹤0.01% 3466

Other funds holding NAVB

ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Northwestern Mutual Wealth Management's NAVB Position: Q3 2023 in Review

Northwestern Mutual Wealth Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2023, closing a stake of 110 shares — an estimated $10 sold.

Northwestern Mutual Wealth Management first reported a position in NAVB in Q4 2021 and held it in 2 quarters. The position peaked at $10 in Q2 2023. 24 funds tracked by Wall St. Rank hold NAVB as of Q3 2023.

  • Northwestern Mutual Wealth Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2023 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 110 Navidea Biopharmaceuticals Inc. shares in Q3 2023, an estimated $10.
  • Northwestern Mutual Wealth Management first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2021 and held it in 2 quarters.
  • Northwestern Mutual Wealth Management's Navidea Biopharmaceuticals Inc. position peaked at $10 in Q2 2023.
  • 24 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2023.

Based on Northwestern Mutual Wealth Management's 13F filing for Q3 2023, filed 14 Nov 2023.